Optimer Pharmaceuticals

Optimer Pharmaceuticals is a biopharmaceutical company dedicated to discovering, developing, and commercializing anti-infective products, particularly those targeting gastrointestinal infections. The company has advanced two late-stage product candidates, fidaxomicin and Pruvel, which address significant medical needs where existing therapies are inadequate. Optimer's portfolio also includes additional candidates such as CEM-101 and a combination therapy involving OPT-822/OPT-821, reflecting its commitment to developing hospital specialty products that positively impact patient health and the healthcare system. By focusing on treatments for conditions like Clostridium difficile-associated diarrhea, Optimer aims to enhance patient outcomes and alleviate the burden of infectious diseases.